Atley Solutions

🎉 🍾 We have completed the first delivery and installation of the Atley C100 in the US. A truly exceptional achievement by the whole Atley team! Want to learn more about Atley Solutions and the Atley C100? Visit the link in the comments 👇 to read to full press release or get in touch with us! #AtleyC100 #astatine211 #targetedradionuclidetherapy #targetedalphatherapy #radiopharmaceuticals #precisiononcology

Atleys expansion was recently highlighted by the local newsmedia Nya Wermlands-tidningen. We are happy for the exposure and for the interest in working with us following the publication of the article. Are YOU looking for an exciting work challange and to be part of the next frontier in the fight against cancer, please visit Atley Solutions and click join Atley! The Article in NWT can be found here (behind subcription wall): https://lnkd.in/d-CJ-tAq

Atley CEO Milton Lönnroth was recently interviewed in Sveriges Radio about the results of the US election and their potential impacts on companies in Sweden that sell to/in the US.

🎉 🍾 💥 Atley has been included in NyTeknik's list of Sweden’s 33 best startup companies - for the third time! See the full list here: https://lnkd.in/dw2hvGBP Ny Teknik

🎉 We are happy and proud to announce the first installation of the commercial Atley C100 at Minerva Imaging in Copenhagen! Minerva Imaging is a great customer for this first installation, since it will enable both more preclinical studies with novel At-211 radiopharmaceuticals, and the supply of clinical radiopharmaceutical doses. Want to learn more about Atley Solutions and the Atley C100? Visit the link in the comments to read to full press release or get in touch with us! #AtleyC100 #astatine211 #targetedradionuclidetherapy #targetedalphatherapy #radiopharmaceuticals #precisiononcology

📣 💥 Major news in the world of Astatine! We are proud to announce the launch of the Atley C100 - the world’s first commercial module for At-211 radiopharmaceutical manufacturing.   The Atley C100 can both purify At-211 from irradiated cyclotron targets and synthesise At-211 based radiopharmaceuticals in an automated process. The Atley C100 will support the development of targeted cancer treatments, helping researchers take a significant step from the lab to the clinic.   Want to learn more about Atley Solutions and the Atley C100? Visit the link in the comments or get in touch with us! #AtleyC100 #astatine211 #targetedradionuclidetherapy #targetedalphatherapy #radiopharmaceuticals #precisiononcology

Meet CEO Milton Lönnroth and Senior Engineer Dr. Christian Rensch at EANM in Hamburg. Are you interested in At-211? Atley supplies the radionuclide itself, as well as tools and services for radiopharmaceutical development and manufacturing. Contact us to set up a meeting: info@atley.com +46 10 750 08 11 #astatine211 #radiopharmaceuticals #precisiononcology #targetedradionuclidetherapy #targetedalphatherapy

📣 Great news! We are proud to announce our involvement in the Thera4Care consortium, led by GE HealthCare, aiming to transform cancer care and advance precision medicine across Europe. As one of 29 partners, Atley Solutions will focus on optimizing the supply chain and standardizing the manufacturing of astatine-211-based radiopharmaceuticals to expand patient access to cutting-edge theranostics. This collaboration aligns with Atley Solutions' commitment to innovation in cancer treatment, driving progress towards a future where personalized care is available to all. Want to learn more about Thera4Care and our role in the project? Visit the link in the comments or get in touch with us! #Thera4Care #astatine211 #targetedradionuclidetherapy #targetedalphatherapy #radiopharmaceuticals #precisiononcology

We had a greAt(-211) time at the 3rd Global Meeting of COST NOAR Astatine! It is fantastic to see how far this group has come in three short years, exemplified by the attendance at the meetings growing from around 50 people the first year to over 150 people this year. We had the pleasure of sharing on stage what Atley is doing to improve the supply of At-211 in Europe through strategic collaborations with existing cyclotron facilities. By providing Bi-209 targets customised to specific cyclotron models, we aim to bring three new At-211 producers online within the next 12 months. Are you interested in getting access to this At-211? Please reach out to us here, or via email at info@atley.com #astatine211 #keenonastatine #astateam #radiopharmaceuticals #targetedradionuclidetherapy

Come meet Atley at the 3rd Global Meeting of COST NOAR Astatine from the 1st to the 3rd of October 2024 in Nantes. Atley's three Co-Founders Milton Lönnroth (CEO), Emma Aneheim (CSO), and Sture Lindegren will be in attendance, as well as Radiochemist Ellinor Hansson. Don't miss the opportunity to hear Milton and Emma on stage at 15:30 on the 2nd of October, where we promise to share some exiting news regarding Atley's progress. Atley is also the proud sponsor of the Gala dinner in the evening of the 2nd of October. Please stop by our booth to say hello! #noar #astatine211 #targetedradionuclidetherapy #targetedalphatherapy #radiopharmaceuticals #precisiononcology